Mersana Therapeutics, Inc.
MRSN
$0.3977
-$0.0023-0.58%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -69.19M | -74.62M | -104.77M | -134.81M | -171.67M |
| Total Depreciation and Amortization | 1.63M | 1.68M | 1.70M | 1.62M | 1.52M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 15.96M | 16.94M | 16.86M | 18.58M | 20.03M |
| Change in Net Operating Assets | -30.74M | -39.05M | -46.34M | -57.92M | -18.76M |
| Cash from Operations | -82.34M | -95.05M | -132.56M | -172.53M | -168.88M |
| Capital Expenditure | -132.00K | -518.00K | -990.00K | -1.39M | -2.17M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 11.57M | -17.90M | 57.88M | 47.33M | 122.05M |
| Cash from Investing | 11.44M | -18.42M | 56.89M | 45.94M | 119.88M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -2.23M | -201.00K | -243.00K | -262.00K | -262.00K |
| Issuance of Common Stock | 6.32M | 6.25M | 6.25M | 79.30M | 95.17M |
| Repurchase of Common Stock | -- | -- | -81.00K | -81.00K | -81.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 0.00 | 0.00 | 0.00 | -150.00K |
| Cash from Financing | 4.09M | 6.05M | 5.93M | 78.96M | 94.68M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -66.81M | -107.42M | -69.73M | -47.64M | 45.68M |